Skip to main content
TipRanks
Go Ultimate75% OFF

Exagen (E08A) AI Stock Analysis

0 Followers
DE:E08A

Exagen

(Frankfurt:E08A)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Strong Revenue Growth and Gross MarginsRapid revenue expansion combined with stable gross margins indicates meaningful demand and sound test-level economics. If Exagen sustains growth while increasing operating leverage, the existing revenue base can support improving profitability and strengthen the company’s position in autoimmune diagnostics over the next several quarters.
Negative Factors
Persistent UnprofitabilityDespite strong top-line growth, Exagen remains materially loss-making, showing that current scale has not yet produced sustainable earnings. Continued operating losses could constrain reinvestment and leave the company dependent on further growth, cost discipline, and operating leverage to reach its targeted adjusted EBITDA breakeven.

Exagen (E08A) vs. iShares MSCI Germany ETF (EWG)

-80%-60%-40%-20%0%20%DE:E08A-45.12%EWG+3.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 96.95M
Dividend Yield
―
Average Volume (3M)
111
Price to Earnings (P/E)
-5.0
Beta (1Y)
0.96
Revenue Growth
8.32%
EPS Growth
22.28%
Country
Germany
Employees
216
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Exagen Business Overview & Revenue Model

Company Description

Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheu...

Exagen Earnings Call Summary

Earnings Call Date:Nov 10, 2026(Q3-2026)|% Change Since:-30.59%|Next Earnings Date:Mar 16, 2027
Earnings Call SentimentPositive

The call was strongly positive, with record quarterly revenue, double-digit year-to-date revenue growth, improving adjusted EBITDA, rising ASP, expanding commercial productivity, strong Pharma Services growth, balance sheet strengthening and meaningful progress toward the myositis launch. The principal challenges were modest third-quarter volume growth, normal seasonal effects, continued adjusted EBITDA losses, uncertain PAMA implementation and no update on the AVISE CTD LCD. Highlights significantly outweighed lowlights.

Positive Updates

Record Third-Quarter Revenue and Reiterated Guidance
Third-quarter revenue was $18.4 million, the best third quarter in company history and up 7% year-over-year. Year-to-date revenue grew more than 11%, and full-year 2026 revenue guidance was reiterated at $72 million to $75 million.

Negative Updates

Moderate Third-Quarter Test Volume Growth
Third-quarter AVISE CTD test volume grew 2% year-over-year, below the higher growth rates seen earlier. Management attributed the result to a tougher year-over-year comparison, fewer clinic days from summer vacations and normal second-half seasonality.

Company Guidance

Exagen reiterated 2026 full year revenue guidance of $72 million to $75 million, assuming high single-digit volume growth and mid-single-digit full year ASP growth compared to the fourth quarter 2025 exit rate, with typical second half volume seasonality and a growing contribution from Pharma Services; management also expects high single digits volume growth, low to mid-single digits ASP growth and revenue growth in the double digits on an annual basis, targets an ASP of at least 50% of Medicare reimbursement or approximately $600 to $650 per test over time, expects gross margin to progress to the mid-60s over time, and believes that at $80 million and around a 60% gross margin it should be right at breakeven on an adjusted EBITDA basis; the myositis offering is on track for launch in early '27, with the validation package expected by the end of January, while potential PAMA impact is expected to be low single-digit impact if it were to be realized fully.

Exagen Risk Analysis

Exagen disclosed 73 risk factors in its most recent earnings report. Exagen reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Exagen Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:E08A against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SERASERA54Neutral$75.16M-2.82-52.54%―1.05%13.67%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ACRSACRS48Neutral$555.14M-6.03-59.20%―-59.34%57.30%
PREPRE48Neutral$174.63M-2.03-74.79%―176.11%-39.52%
MDXHMDXH40Underperform$11.20M-0.11306.18%―3.67%-19.54%
STIMSTIM40Underperform$96.38M-3.85-127.86%―23.01%60.22%

* Healthcare Sector Average

Performance Comparison

0%100%DE:E08AACRSMDXHSTIMPRESERADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:E08A and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:E08AExagen3.54-2.96-45.54%
ACRSAclaris Therapeutics Inc.3.500.7527.27%
MDXHMdxhealth S.A.0.12-3.45-96.72%
STIMNeuronetics1.24-0.03-2.36%
PREPrenetics Group Limited10.31-3.79-26.88%
SERASera Prognostics, Inc.1.89-1.49-44.08%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.